Literature DB >> 11399867

Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene.

T Funato1, K Kozawa, S Fujimaki, T Miura, M Kaku.   

Abstract

BACKGROUND: The c-erbB-2 oncogene encodes a transmembrane tyrosine kinase receptor and its abnormal expression may be related to the prognosis of gastric cancer. Gastric cancer is relatively resistant to various drugs, including cisplatin. Cisplatin is widely used in cancer chemotherapy, but the mechanisms of drug resistance are not yet known.
METHODS: We used the human gastric cancer cell lines MKN-7 and KATO-III, which express the c-erbB-2 oncogene, as a model for relative resistance to cisplatin. We investigated whether inhibition with antisense oligonucleotides against c-erbB-2 increased the sensitivity of MKN-7 and KATO-III cells to cisplatin.
RESULTS: Antisense oligonucleotides for c-erbB-2 inhibited the expression of c-erbB-2 mRNA and protein and increased sensitivity to cisplatin, but not to other drugs, in MKN-7 and KATO-III cells. Cell growth was also inhibited by c-erbB-2 antisense oligonucleotides but not sense oligonucleotides.
CONCLUSION: These findings indicate that c-erbB-2 expression in gastric cancer is one of the factors related to cisplatin sensitivity, and that anti-c-erbB-2 antisense oligonucleotides induced increased sensitivity to cisplatin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11399867     DOI: 10.1159/000048537

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  7 in total

Review 1.  Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.

Authors:  J C Becker; C Muller-Tidow; H Serve; W Domschke; T Pohle
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

2.  Heat shock protein 70 antisense oligonucleotide inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901.

Authors:  Zhi-Gang Zhao; Wen-Lu Shen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

Review 3.  Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail?

Authors:  F Gieseler; P Rudolph; G Kloeppel; U R Foelsch
Journal:  Int J Colorectal Dis       Date:  2003-05-28       Impact factor: 2.571

4.  Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies.

Authors:  José Cangiano; Barbara A Centeno; Christopher R Garrett; William Cáceres; Ana de Jesús; Ji-Hyun Lee; Orestes Pavía; Richard Jove; Luis Báez; Daniel M Sullivan; Carlos A Muro-Cacho; Teresita Muñoz-Antonia
Journal:  Dig Dis Sci       Date:  2008-01-26       Impact factor: 3.199

5.  HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain.

Authors:  E U Cidon; R G Centeno; E G Lagarto; J I Peral
Journal:  J Oncol       Date:  2011-10-27       Impact factor: 4.375

6.  Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins.

Authors:  Yongping Liu; Yang Ling; Qiufeng Qi; Ming Zhu; Meizhen Wan; Yaping Zhang; Changsong Zhang
Journal:  Oncol Lett       Date:  2014-12-12       Impact factor: 2.967

7.  Dysregulation of mRNA profile in cisplatin-resistant gastric cancer cell line SGC7901.

Authors:  Xiao-Que Xie; Qi-Hong Zhao; Hua Wang; Kang-Sheng Gu
Journal:  World J Gastroenterol       Date:  2017-02-21       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.